VERTEX PHARMACEUTICALS INC / MA Deferred Foreign Income Tax Expense (Benefit)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Deferred Foreign Income Tax Expense (Benefit) of $38.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA deferred foreign income tax expense (benefit) for fiscal 2025 was $38.30M, a 72.37% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA deferred foreign income tax expense (benefit) for fiscal 2024 was $138.60M, a 150.63% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA deferred foreign income tax expense (benefit) for fiscal 2023 was $55.30M, a 60.24% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA deferred foreign income tax expense (benefit) for fiscal 2022 was $139.10M.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month | Deferred Foreign Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $38.30M 10-K · filed 2026-02-13 | |
| 2024-12-31 | $138.60M 10-K · filed 2026-02-13 | |
| 2023-12-31 | $55.30M 10-K · filed 2026-02-13 | |
| 2022-12-31 | $139.10M 10-K · filed 2025-02-13 | |
| 2021-12-31 | -$98.40M 10-K · filed 2024-02-15 | |
| 2020-12-31 | -$239.60M 10-K · filed 2023-02-10 | -$239.58M 10-K · filed 2021-02-11 |
| 2019-12-31 | -$24.80M 10-K · filed 2022-02-09 | -$24.80M 10-K · filed 2020-02-13 |
| 2018-12-31 | -$364.92M 10-K · filed 2021-02-11 | |
| 2017-12-31 | -$3.22M 10-K · filed 2020-02-13 | |
| 2016-12-31 | -$3.36M 10-K · filed 2019-02-13 | |
| 2015-12-31 | -$355.00K 10-K · filed 2018-02-15 | |
| 2014-12-31 | $0.00 10-K · filed 2017-02-23 | |
| 2013-12-31 | -$127.59M 10-K · filed 2016-02-16 | |
| 2012-12-31 | $0.00 10-K · filed 2015-02-13 | |
| 2011-12-31 | -$32.69M 10-K · filed 2014-02-11 | |
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |